To include your compound in the COVID-19 Resource Center, submit it here.

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

Dutch family office’s investments have DCprime ready to broaden portfolio, investor base

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product portfolio and clinical testing of its lead asset, and to establish in-house manufacturing capabilities.

DCprime B.V. is backed solely by the Van Herk Group, a Dutch life sciences investor

Read the full 645 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers